Cover Image
市場調查報告書

PharmaPoint:A、B型血友病基因重組型製劑補充療法 - 全球醫藥品市場預測與市場分析

PharmaPoint: Hemophilia A and B - Global Drug Forecast and Market Analysis to 2026

出版商 GlobalData 商品編碼 354677
出版日期 內容資訊 英文 404 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:A、B型血友病基因重組型製劑補充療法 - 全球醫藥品市場預測與市場分析 PharmaPoint: Hemophilia A and B - Global Drug Forecast and Market Analysis to 2026
出版日期: 2017年07月01日 內容資訊: 英文 404 Pages
簡介

A、B型血友病基因重組型製劑市場2016年的銷售額,在主要7個國家是66億8千萬美元。2026年預計達到79億7千萬美元,以1.8%的年複合成長率成長。

本報告提供A、B型血友病基因重組型製劑補充療法市場相關調查分析,疾病的概要與指南,競爭情形,主要藥物的詳細資訊 (產品說明,安全性,有效性) 、SWOT分析,銷售額預測,影響分析 (趨勢,推動因素、阻礙因素) 等相關的系統性資訊。

第1章 目錄

第2章 摘要整理

第3章 簡介

第4章 疾病概要

  • 病因、病理生理學
    • 病因
    • 病理生理學
  • 分類
  • 症狀
    • A、B型血友病
    • 抑制劑
  • 預後、QOL

第5章 流行病學

  • 疾病的背景
  • 危險因素和合併症
  • 全球趨勢
  • 預測手法
    • 資訊來源
    • 預測的前提條件與手法
    • 確診的患者數
    • 確診的A、B型血友病患者數:各重症度
    • 確診的A、B型血友病患者數:各抑制劑
  • 流行病學預測:A型血友病
    • 確診的患者數
    • 確診的患者數:各年齡
    • 確診的患者數:性別
    • 確診的患者數:各重症度
    • 確診的患者數:A型血友病抑制劑
  • 流行病學預測:B型血友病
    • 確診的患者數
    • 確診的患者數:各年齡
    • 確診的患者數:性別
    • 確診的患者數:各重症度
    • 確診的患者數:B型血友病抑制劑
  • 流行病學預測:A、B型血友病
    • 確診的患者數
    • 確診的患者數:各年齡
    • 確診的患者數:性別
    • 確診的患者數:各重症度
    • 確診的患者數:A、B型血友病抑制劑
  • 議論
    • 流行病學的趨勢相關考察
    • 分析的限制
    • 分析的優勢

第6章 疾病的管理

  • 治療概要
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第7章 競爭評估

  • 概要
  • 產品簡介:A型血友病
  • 產品簡介:B型血友病
  • 產品簡介:A、B型血友病

第8章 機會及未滿足需求

  • 概要
  • 未治療患者的抑制劑發生風險低
  • 抑制劑患者的更有效的治療方法
  • 效果持續的藥物及更便利的投藥途徑等

第9章 開發平台評估

  • 概要
  • 後期開發的候補藥:A型血友病
  • 後期開發的候補藥:A型血友病
  • 後期開發的候補藥:A、B型血友病
  • 初期開發中的有潛力的藥劑

第10章 現在、未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • Bayer
    • Bioverativ
    • CSL Behring
    • Novo Nordisk
    • Pfizer
    • Roche
    • Shire

第11章 市場預測

  • 全球市場
  • 美國
  • EU5個國家
  • 日本

第12章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC148PIDR

Hemophilia A and B are rare, recessive, X-linked genetic disorders that almost exclusively afflict males and are characterized by the failure of blood to form normal clots after damage to veins and tissue. Hemophilia A is significantly more predominant than hemophilia B. According to the Centers for Disease Control and Prevention (CDC), there are approximately 20,000 patients in the US with hemophilia, and hemophilia A is four times more common than hemophilia B.

It is estimated that the total hemophilia A and B markets in the 7MM had a value of $6.68Bn in 2016. This analysis includes the sales of desmopressin (DDVAP), plasma-derived and recombinant factor concentrates, and alternative coagulation promoters (ACPs).

Hemophilia sales are forecast to grow to $7.97bn in 2026, at a modest Compound Annual Growth Rate (CAGR) of 1.8%. The US represents the largest market in hemophilia, accounting for approximately 60% of total product sales in 2016 and 2026. The five major European markets (5EU: France, Germany, Italy, Spain, and the UK) represents the second largest market region, accounting for approximately 32% of the total product sales in 2016 and 31% in 2026.

Major drivers of the hemophilia market in the 7MM over the forecast period include -

  • Increasing rates of routine prophylaxis in pediatric and adult hemophilia A and B.
  • The introduction and uptake of new long-acting factors and ACPs.

Traditionally, the hemophilia market has been dominated by short-acting rFVIII or FIX concentrates. However, in recent years the hemophilia market has become increasingly competitive due to the approval of extended half-life products that can reduce the burden associated with prophylaxis. These improvements have mainly benefited hemophilia B patients, while a substantial unmet need remains for hemophilia A patients and patients with inhibitors who do not respond to standard treatments.

The report "PharmaPoint: Hemophilia A and B - Global Drug Forecast and Market Analysis to 2026" provides overview of hemophilia, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

In particular, this report provides the following -

  • Annualized hemophilia therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in nine patient segments and two treatment strategies (episodic and prophylactic treatment), forecast from 2016 to 2026.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the hemophilia therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for hemophilia. The most promising candidate in Phase III development is profiled.
  • Analysis of the current and future market competition in the global hemophilia market. Insightful review of the key industry drivers, restraints and, challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report: Amunix, Apitope, Aptevo Therapeutics, Bayer, Baxter, Baxalta, Biogen, BioMarin, Bioverativ, Catalyst Biosciences, Chugai, CSL Behring, Dimension Therapeutics, LFB, Novo Nordisk, Octapharma, Opko Biologics, Pfizer, Revo Biologics, Roche/Genentech, Sangamo Therapeutics, Shire, Spark Therapeutics, uniQure, Xenetic Biosciences.

Scope:

  • Overview of hemophilia, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized hemophilia therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in nine patient segments and two treatment strategies (episodic and prophylactic treatment), forecast from 2016 to 2026.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the hemophilia therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for hemophilia. The most promising candidate in Phase III development is profiled.
  • Analysis of the current and future market competition in the global hemophilia market. Insightful review of the key industry drivers, restraints and, challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy:

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global hemophilia market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global hemophilia market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Executive Summary

  • 2.1. Sales for Hemophilia A and B Recombinant Therapies by Region, 2016-2026
  • 2.2. Long-Acting rFVIIIs Have Not Lived Up to Expectations
  • 2.3. Inhibitor Segment to Devalue Post-Alternative Coagulation Promoter Launch
  • 2.4. Roche's Emicizumab to Radically Impact Hemophilia A and Inhibitor Segments
  • 2.5. Treatment Cost to Remain a Major Unmet Need
  • 2.6. New Comers to Take Over Market Space From Established Companies
  • 2.7. What Do Physicians Think?

3. Introduction

  • 3.1. Catalyst
  • 3.2. Related Reports
  • 3.3. Upcoming Related Reports

4. Disease Overview

  • 4.1. Etiology and Pathophysiology
    • 4.1.1. Etiology
    • 4.1.2. Pathophysiology
  • 4.2. Classification
  • 4.3. Symptoms
    • 4.3.1. Hemophilia A and B
    • 4.3.2. Inhibitors
  • 4.4. Prognosis and Quality of Life

5. Epidemiology

  • 5.1. Disease Background
  • 5.2. Risk Factors and Comorbidities
  • 5.3. Global and Historical Trends
  • 5.4. Forecast Methodology
    • 5.4.1. Sources
    • 5.4.2. Forecast Assumptions and Methods
    • 5.4.3. Diagnosed Prevalent Cases
    • 5.4.4. Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity
    • 5.4.5. Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Inhibitors
  • 5.5. Epidemiological Forecast for Hemophilia A(2016-2026)
    • 5.5.1. Diagnosed Prevalent Cases of Hemophilia A
    • 5.5.2. Age-Specific Diagnosed Prevalent Cases of Hemophilia A
    • 5.5.3. Sex-Specific Diagnosed Prevalent Cases of Hemophilia A
    • 5.5.4. Diagnosed Prevalent Cases of Hemophilia A by Severity
    • 5.5.5. Diagnosed Prevalent Cases of Hemophilia A with Inhibitors
  • 5.6. Epidemiological Forecast for Hemophilia B(2016-2026)
    • 5.6.1. Diagnosed Prevalent Cases of Hemophilia B
    • 5.6.2. Age-Specific Diagnosed Prevalent Cases of Hemophilia B
    • 5.6.3. Sex -Specific Diagnosed Prevalent Cases of Hemophilia B
    • 5.6.4. Diagnosed Prevalent Cases of Hemophilia B by Severity
    • 5.6.5. Diagnosed Prevalent Cases of Hemophilia B with Inhibitors
  • 5.7. Epidemiological Forecast for Hemophilia A and Hemophilia B(2016-2026)
    • 5.7.1. Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
    • 5.7.2. Age-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
    • 5.7.3. Sex -Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
    • 5.7.4. Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity
    • 5.7.5. Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors
  • 5.8. Discussion
    • 5.8.1. Epidemiological Forecast Insight
    • 5.8.2. Limitations of the Analysis
    • 5.8.3. Strengths of the Analysis

6. Disease Management

  • 6.1. Treatment Overview
    • 6.1.1. Treatment Guidelines
    • 6.1.2. Clinical Practice
  • 6.2. US
    • 6.2.1. Clinical Practice
  • 6.3. France
    • 6.3.1. Clinical Practice
  • 6.4. Germany
    • 6.4.1. Clinical Practice
  • 6.5. Italy
    • 6.5.1. Clinical Practice
  • 6.6. Spain
    • 6.6.1. Clinical Practice
  • 6.7. UK
    • 6.7.1. Clinical Practice
  • 6.8. Japan
    • 6.8.1. Clinical Practice

7. Competitive Assessment

  • 7.1. Overview
  • 7.2. Product Profiles - Hemophilia A
    • 7.2.1. Short Acting rFVIII
    • 7.2.2. Long Acting rFVIII
    • 7.2.3. Plasma-Derived FVIII Concentrates
    • 7.2.4. Desmopressin Acetate
  • 7.3. Product Profiles - Hemophilia B
    • 7.3.1. Short Acting rFIX
    • 7.3.2. Long Acting FIX
    • 7.3.3. Plasma-Derived FIX Concentrates
  • 7.4. Product Profiles - Hemophilia A and B with Inhibitors
    • 7.4.1. NovoSeven RT(Eptacog Alfa)
    • 7.4.2. Feiba NF(Activated Prothrombin Complex Concentrate)

8. Unmet Needs and Opportunities

  • 8.1. Overview
  • 8.2. Reduction in Risk of Inhibitor Development in Previously Untreated Patients
    • 8.2.1. Unmet Need
    • 8.2.2. Gap Analysis
    • 8.2.3. Opportunity
  • 8.3. More Effective Treatments for Patients with Inhibitors
    • 8.3.1. Unmet Need
    • 8.3.2. Gap Analysis
    • 8.3.3. Opportunity
  • 8.4. Longer-Lasting Agents and More Convenient Administration Routes
    • 8.4.1. Unmet Need
    • 8.4.2. Gap Analysis
    • 8.4.3. Opportunity
  • 8.5. Treatments to Cure the Disease
    • 8.5.1. Unmet Need
    • 8.5.2. Gap Analysis
    • 8.5.3. Opportunity
  • 8.6. Decreasing the Costs Associated with Prophylaxis
    • 8.6.1. Unmet Need
    • 8.6.2. Gap Analysis
    • 8.6.3. Opportunity
  • 8.7. Individualized Prophylaxis
    • 8.7.1. Unmet Need
    • 8.7.2. Gap Analysis
    • 8.7.3. Opportunity

9. Pipeline Assessment

  • 9.1. Overview
  • 9.2. Late-Stage Development Candidates - Hemophilia A
    • 9.2.1. BAY 94-9027(Damoctocog Alfa Pegol)
    • 9.2.2. N8-GP(Turoctocog Alfa Pegol)
    • 9.2.3. Emicizumab(ACE-910, RG-6013)
    • 9.2.4. Fitusiran(ALN-AT3, SAR-439774)
  • 9.3. Late-Stage Development Candidates - Hemophilia B
  • 9.4. Late-Stage Development Candidates - Hemophilia A and B Patients with Inhibitors
    • 9.4.1. LR-769(rhFVIIa)
    • 9.4.2. Obizur(Susoctocog Alfa)
    • 9.4.3. CSL-689(rVIIa-FP)
    • 9.4.4. BAX-817(rFVIIa BI)
  • 9.5. Promising Approaches in Early-Stage Development
    • 9.5.1. Alternative Coagulation Promoters - Tissue Factor Pathway Inhibitors
    • 9.5.2. Gene Therapies
    • 9.5.3. Replacement Strategies
    • 9.5.4. Strategies to Prevent and Manage Inhibitors
    • 9.5.5. Other Drugs in Development

10. Current and Future Players

  • 10.1. Overview
  • 10.2. Trends in Corporate Strategy
  • 10.3. Company Profiles
    • 10.3.1. Bayer
    • 10.3.2. Bioverativ
    • 10.3.3. CSL Behring
    • 10.3.4. Novo Nordisk
    • 10.3.5. Pfizer
    • 10.3.6. Roche
    • 10.3.7. Shire

11. Market Outlook

  • 11.1. Global Markets
    • 11.1.1. Forecast
    • 11.1.2. Drivers and Barriers - Global Market
  • 11.2. US
    • 11.2.1. Forecast
    • 11.2.2. Key Events
    • 11.2.3. Drivers and Barriers
  • 11.3. 5EU
    • 11.3.1. Forecast
    • 11.3.2. Key Events
    • 11.3.3. Drivers and Barriers - 5EU
    • 11.3.4. Drivers and Barriers - France
    • 11.3.5. Drivers and Barriers - Germany
    • 11.3.6. Drivers and Barriers - Italy
    • 11.3.7. Drivers and Barriers - Spain
    • 11.3.8. Drivers and Barriers - UK
  • 11.4. Japan
    • 11.4.1. Forecast
    • 11.4.2. Key Events
    • 11.4.3. Drivers and Barriers

12. Appendix

  • 12.1. Bibliography
  • 12.2. Abbreviations
  • 12.3. Methodology
  • 12.4. Forecasting Methodology
    • 12.4.1. Diagnosed Hemophilia Patients
    • 12.4.2. Percent Drug-Treated Patients
    • 12.4.3. Drugs Included in Each Therapeutic Class
    • 12.4.4. Launch and Patent Expiry Dates
    • 12.4.5. General Pricing Assumptions
    • 12.4.6. Individual Drug Assumptions
    • 12.4.7. Pricing of Pipeline Agents
  • 12.5. Primary Research - KOLs Interviewed for this Report
  • 12.6. Primary Research - Prescriber Survey
  • 12.7. Real-World Data
  • 12.8. About the Authors
    • 12.8.1. Analyst
    • 12.8.2. Reviewer
    • 12.8.3. Therapy Area Director
    • 12.8.4. Epidemiologists
    • 12.8.5. Reviewers
    • 12.8.6. Global Director of Therapy Analysis and Epidemiology
    • 12.8.7. Global Head and EVP of Healthcare Operations and Strategy
  • 12.9. About GlobalData
  • 12.10. Contact Us
  • 12.11. Disclaimer

List of Tables

  • Table 1: Hemophilia A and B: Key Metrics in the Seven Major Markets, 2016-2026
  • Table 2: Classification of Hemophilia A and B
  • Table 3: Symptoms of Hemophilia A and B
  • Table 4: Relationship of Bleeding Severity with Clotting Factor Level.
  • Table 5: Comorbidities for Hemophilia
  • Table 6: 7MM, Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, Selected Years 2016-2026.
  • Table 7: 7MM, Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, N, Selected Years 2016-2026.
  • Table 8: 7MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, Selected Years 2016-2026.
  • Table 9: 7MM Treatment Guidelines for Hemophilia
  • Table 10: Most Prescribed Hemophilia A and B Drugs in the Global Markets, 2016
  • Table 11: Definition of Therapeutic Protocols in Hemophilia
  • Table 12: Country Profile - US, 2016
  • Table 13: Country Profile - France, 2016
  • Table 14: Country Profile - Germany, 2016
  • Table 15: Country Profile - Italy, 2016
  • Table 16: Country Profile - Spain, 2016
  • Table 17: Country Profile - UK, 2016
  • Table 18: Country Profile - Japan, 2016
  • Table 19: Leading Replacement Therapies for Hemophilia A and B and Patients with Inhibitors, 2017
  • Table 20: Product Profile - Recombinate
  • Table 21: Summary of the Results of the Pivotal Trial of Recombinate
  • Table 22: Recombinate SWOT Analysis, 2017
  • Table 23: Product Profile - Kogenate FS
  • Table 24: Summary of the Results from the Trial that Led to the Approval of Kogenate FS
  • Table 25: Summary of the Results from the Trial that Studies Kogenate FS in Pediatric Prophylaxis
  • Table 26: Kogenate FS SWOT Analysis, 2017
  • Table 27: Product Profile -Helixate FS
  • Table 28: Helixate FS SWOT Analysis, 2017
  • Table 29: Product Profile - Advate
  • Table 30: Summary of the Results from the Part 2 Phase II/III Pivotal Trial of Advate
  • Table 31: Summary of the Results from the Phase IV Prophylaxis Study of Advate
  • Table 32: Advate SWOT Analysis, 2017
  • Table 33: Product Profile - Kovaltry
  • Table 34: Summary of the LEOPOLD I and II Trials of Kovaltry
  • Table 35: Summary of the LEOPOLD Kids Trial of Kovaltry
  • Table 36: Kovaltry SWOT Analysis, 2017
  • Table 37: Product Profile - Xyntha/ReFacto AF
  • Table 38: Summary of the Pivotal Trial of Xyntha
  • Table 39: Xyntha/ReFacto AF SWOT Analysis, 2017
  • Table 40: Product Profile - NovoEight
  • Table 41: Summary of the Results of The Guardian 1 Trial of NovoEight
  • Table 42: Summary of the Results of The Guardian 3 Trial of NovoEight
  • Table 43: NovoEight SWOT Analysis, 2017
  • Table 44: Product Profile - Nuwiq
  • Table 45: Summary of the Results from the GENA-01, GENA-08, and GENA-03 Trials of Nuwiq
  • Table 46: Nuwiq SWOT Analysis, 2017
  • Table 47: Product Profile - Eloctate
  • Table 48: Summary of the Results of the A-LONG Trial of Eloctate
  • Table 49: Eloctate SWOT Analysis, 2017
  • Table 50: Product Profile - Adynovate
  • Table 51: Summary of the Results of the PROLONG-ATE Trial of Adynovate
  • Table 52: Summary of the Results of the BAX855 Pediatric Trial of Adynovate
  • Table 53: Adynovate SWOT Analysis, 2017
  • Table 54: Product Profile - Afstyla
  • Table 55: Summary of the Results of the AFFINITY and Pediatric Trials of Afstyla
  • Table 56: Afstyla SWOT Analysis, 2017
  • Table 57: Marketed Plasma-Derived Replacement Therapies for Hemophilia A Patients, 2017
  • Table 58: Product Profile - BeneFIX
  • Table 59: Summary of the Results of the Phase III Trial of BeneFIX
  • Table 60: Summary of the Results that Proved the Effectiveness of BeneFIX as Prophylaxis Regimen
  • Table 61: Summary of the Results of the Phase III BeneFIX 1010 Study
  • Table 62: BeneFIX SWOT Analysis, 2017
  • Table 63: Product Profile - Rixubis
  • Table 64: Summary of the Results of the Pivotal Trial of Rixubis
  • Table 65: Summary of the Results of the Pediatric Trial of Rixubis
  • Table 66: Rixubis SWOT Analysis, 2017
  • Table 67: Product Profile - IXinity
  • Table 68: Summary of the Results of the Pivotal Trial of IXinity
  • Table 69: IXinity SWOT Analysis, 2017
  • Table 70: Product Profile - Alprolix
  • Table 71: Summary of the Results of the B-LONG Trial of Alprolix
  • Table 72: Summary of the Results of the Kids B-Long Trial of Alprolix
  • Table 73: Alprolix SWOT Analysis, 2017
  • Table 74: Product Profile - Idelvion
  • Table 75: Summary of the Results of the CSL654_3001 Trial of Idelvion
  • Table 76: Summary of the Results of the CSL654_3002 Trial of Idelvion
  • Table 77: Idelvion SWOT Analysis, 2017
  • Table 78: Product Profile - Rebynin
  • Table 79: Results of the Paradigm 2 Trial of Rebynin
  • Table 80: Results of the Pediatric Paradigm 5 Trial of Rebynin
  • Table 81: Rebynin SWOT Analysis, 2017
  • Table 82: Marketed Plasma-Derived Replacement Therapies for Hemophilia B Patients, 2017
  • Table 83: Product Profile - NovoSeven RT
  • Table 84: Summary of the Results of the Phase III Trial of NovoSeven
  • Table 85: NovoSeven RT SWOT Analysis, 2017
  • Table 86: Product Profile - Feiba NF
  • Table 87: Summary of the Results of the PROOF Trial of Feiba NF
  • Table 88: Feiba NF SWOT Analysis, 2017
  • Table 89: Unmet Needs and Opportunities in Hemophilia
  • Table 90: Product Profile - BAY 94-9027
  • Table 91: Efficacy of BAY 94-9027 in the PROTECT VIII study
  • Table 92: BAY 94-9027 SWOT Analysis, 2017
  • Table 93: Product Profile - N8-GP
  • Table 94: Efficacy of N8-GP in the Pathfinder 2 and 5Trials
  • Table 95: N8-GP SWOT Analysis, 2017
  • Table 96: Product Profile - Emicizumab
  • Table 97: Efficacy of Emicizumab in a Japanese Phase I/II Study
  • Table 98: Emicizumab SWOT Analysis, 2016
  • Table 99: Product Profile - Fitusiran

Table 100 : Efficacy of Fitusiran in the Part-D Phase I Study 246

  • Table 101: Fitusiran SWOT Analysis, 2017
  • Table 102: Product Profile - LR-769
  • Table 103: LR-769 SWOT Analysis, 2017
  • Table 104: Product Profile - Obizur
  • Table 105: Obizur SWOT Analysis, 2017
  • Table 106: Product Profile - CSL-689
  • Table 107: CSL-689 SWOT Analysis, 2017
  • Table 108: Product Profile - BAX-817
  • Table 109: BAX-817 SWOT Analysis, 2017
  • Table 110: TFPI inhibitors - Early-Stage Pipeline, 2017
  • Table 111: Hemophilia A and B Gene Therapies - Early-Stage Pipeline, 2017
  • Table 112: Hemophilia A and B Recombinant Replacement Therapies - Early-Stage Pipeline, 2017
  • Table 113: Drugs in Development for Hemophilia, 2016
  • Table 114: Key Companies in the Hemophilia A and B Recombinant Therapies Market, 2016-2026
  • Table 115: Bayer's Hemophilia Portfolio Assessment, 2015
  • Table 116: Bayer SWOT Analysis, 2017
  • Table 117: Bioverativ/Sobi's Hemophilia Portfolio Assessment, 2017
  • Table 118: Bioverativ SWOT Analysis, 2017
  • Table 119: CSL Behring's Hemophilia Recombinant Portfolio Assessment, 2017
  • Table 120: CSL Behring SWOT Analysis, 2017
  • Table 121: Novo Nordisk's Hemophilia Recombinant Portfolio Assessment, 2017
  • Table 122: Novo Nordisk SWOT Analysis, 2017
  • Table 123: Pfizer's Hemophilia Recombinant Portfolio Assessment, 2017
  • Table 124: Pfizer SWOT Analysis, 2017
  • Table 125: Roche's Hemophilia Recombinant Portfolio Assessment, 2017
  • Table 126: Roche SWOT Analysis, 2017
  • Table 127: Shire's Hemophilia Recombinant Portfolio Assessment, 2017
  • Table 128: Shire SWOT Analysis, 2017
  • Table 129: Global Hemophilia A and B Market - Drivers and Barriers, 2016-2026
  • Table 130: Key Events Impacting Sales for Hemophilia A and B in the US, 2016-2026
  • Table 131: US Hemophilia A and B Market - Drivers and Barriers, 2016-2026
  • Table 132: Key Events Impacting Sales for Hemophilia A and B Therapeutics in the 5EU, 2016-2026
  • Table 133: 5EU Hemophilia A and B Market - Drivers and Barriers, 2016-2026
  • Table 134: French Hemophilia A and B Market - Drivers and Barriers, 2016-2026
  • Table 135: German Hemophilia A and B Market - Drivers and Barriers, 2016-2026
  • Table 136: Italian Hemophilia A and B Market - Drivers and Barriers, 2016-2026
  • Table 137: Spanish Hemophilia A and B Market - Drivers and Barriers, 2016-2026
  • Table 138: UK Hemophilia A and B Market - Drivers and Barriers, 2016-2026
  • Table 139: Key Events Impacting Sales for Hemophilia A and B in Japan, 2016-2026
  • Table 140: Japanese Hemophilia A and B Market - Drivers and Barriers, 2016-2026
  • Table 141: Key Launch Dates
  • Table 142: Key Historical and Projected Patent Expiry Dates
  • Table 143: Average Body Weight Across the 7MM
  • Table 144: Average Cost of Therapy of Plasma-Derived FVIII Concentrates in the 7MM
  • Table 145: Average Cost of Therapy of Recombinate in the 7MM
  • Table 146: Average Cost of Therapy of Kogenate FS in the 7MM
  • Table 147: Average Cost of Therapy of Helixate FS in the 7MM
  • Table 148: Average Cost of Therapy of Advate in the 7MM
  • Table 149: Average Cost of Therapy of Kovaltry in the 7MM
  • Table 150: Average Cost of Therapy of Xyntha in the 7MM
  • Table 151: Average Cost of Therapy of NovoEight in the 7MM
  • Table 152: Average Cost of Therapy of Nuwiq in the 7MM
  • Table 153: Average Cost of Therapy of Eloctate in the 7MM
  • Table 154: Average Cost of Therapy of Adynovate in the 7MM
  • Table 155: Average Cost of Therapy of Afstyla in the 7MM
  • Table 156: Average Cost of Therapy of Plasma-derived FIX Concentrates in the 7MM
  • Table 157: Average Cost of Therapy of BeneFIX in the 7MM
  • Table 158: Average Cost of Therapy of Rixubis in the 7MM
  • Table 159: Average Cost of Therapy of IXinity in the 7MM
  • Table 160: Average Cost of Therapy of Alprolix in the 7MM
  • Table 161: Average Cost of Therapy of Idelvion in the 7MM
  • Table 162: Average Cost of Therapy of NovoSeven in the 7MM
  • Table 163: Average Cost of Therapy of Feiba in the 7MM
  • Table 164: Average Cost of Therapy of DDAVP in the 7MM
  • Table 165: Physicians Surveyed

List of Figures

  • Figure 1: Sales for Hemophilia A and B Therapeutics by Drug Class, 2016-2026
  • Figure 2: Competitive Assessment of Late-Stage Pipeline Agents, 2016-2026
  • Figure 3: Key Company Portfolio Positioning in Hemophilia A and B, 2016-2026
  • Figure 4: 7MM, Age-Standardized Diagnosed Prevalence of Hemophilia A (Cases per 100,000 Population), All Ages, 2016
  • Figure 5: 7MM, Age-Standardized Diagnosed Prevalence of Hemophilia B (Cases per 100,000 Population), All Ages, 2016
  • Figure 6: 7MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
  • Figure 7: 7MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity
  • Figure 8: 7MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors
  • Figure 9: 7MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, 2016
  • Figure 10: 7MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, 2016
  • Figure 11: 7MM, Diagnosed Prevalent Cases of Hemophilia A by Severity, Both Sexes, All Ages, N, 2016
  • Figure 12: 7MM, Diagnosed Prevalent Cases of Hemophilia A with Inhibitors, Both Sexes, All Ages, N, 2016
  • Figure 13: 7MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, 2016
  • Figure 14: 7MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, N, 2016
  • Figure 15: 7MM, Diagnosed Prevalent Cases of Hemophilia B by Severity, Both Sexes, All Ages, N, 2016
  • Figure 16: 7MM, Diagnosed Prevalent Cases of Hemophilia B with Inhibitors, Both Sexes, All Ages, N, 2016
  • Figure 17: 7MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, 2016
  • Figure 18: 7MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, All Ages, N, 2016
  • Figure 19: 7MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity, Both Sexes, All Ages, N, 2016
  • Figure 20: 7MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors, Both Sexes, All Ages, N, 2016
  • Figure 21: Treatment Flowchart for Severe Patients with Inhibitors
  • Figure 22: Competitive Assessment of Late-Stage Pipeline Agents, 2016-2026
  • Figure 23: Overview of the Development Pipeline in Hemophilia, 2016-2026
  • Figure 24: Hemophilia A - Phase III Pipeline, 2017
  • Figure 25: BAY94-9027's Clinical Development in Hemophilia A
  • Figure 26: Clinical and Commercial Positioning of BAY94-9027
  • Figure 27: N8-GP's Clinical Development in Hemophilia A
  • Figure 28: Clinical and Commercial Positioning of N8-GP
  • Figure 29: Emicizumab's Clinical Development in Hemophilia A
  • Figure 30: Clinical and Commercial Positioning of Emicizumab
  • Figure 31: Clinical and Commercial Positioning of Fitusiran
  • Figure 32: Hemophilia A and B with Inhibitors - Phase III Pipeline, 2017
  • Figure 33: LR-769's Clinical Development in Patients with Inhibitors
  • Figure 34: Clinical and Commercial Positioning of LR-769
  • Figure 35: Obizur's Clinical Development in Patients with Inhibitors
  • Figure 36: Clinical and Commercial Positioning of Obizur
  • Figure 37: CSL-689's Clinical Development in Patients with Inhibitors
  • Figure 38: Clinical and Commercial Positioning of CSL-689
  • Figure 39: Clinical and Commercial Positioning of BAX-817
  • Figure 40: Company Portfolio Analysis in Hemophilia A and B, 2016-2026
  • Figure 41: Global Sales of Hemophilia Therapeutics by Company, 2016-2026
  • Figure 42: Global Sales for Hemophilia A and B by Drug Class, 2016-2026
  • Figure 43: Global Sales for Hemophilia A and B Therapeutics by Region, 2016-2026
  • Figure 44: Sales for Hemophilia A and B Therapeutics in the US by Drug Class, 2016-2026
  • Figure 45: Sales for Hemophilia A and B Therapeutics in the 5EU by Drug Class, 2016-2026
  • Figure 46: Sales for Hemophilia A and B Therapeutics in the 5EU by Country, 2016-2026
  • Figure 47: Sales for Hemophilia A and B Therapeutics in Japan by Drug Class, 2016-2026
Back to Top